Centessa Pharmaceuticals PLC ADR (CNTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has a cash flow conversion efficiency ratio of -0.106x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-55.81 Million) by net assets ($526.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Centessa Pharmaceuticals PLC ADR - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CNTA liabilities breakdown for a breakdown of total debt and financial obligations.
Centessa Pharmaceuticals PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Venture Global, Inc.
NYSE:VG
|
0.174x |
|
MERUS N.V. EO -09
F:2GH
|
N/A |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
0.025x |
|
Pegasystems Inc
NASDAQ:PEGA
|
0.201x |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
0.103x |
|
XTC New Energy Materials Xiamen Co Ltd
SHG:688778
|
0.026x |
|
Nice Ltd ADR
NASDAQ:NICE
|
0.049x |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
Annual Cash Flow Conversion Efficiency for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CNTA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.86 Million | $-193.82 Million | -0.368x | -3.99% |
| 2024-12-31 | $401.55 Million | $-142.06 Million | -0.354x | +47.88% |
| 2023-12-31 | $236.24 Million | $-160.34 Million | -0.679x | -13.77% |
| 2022-12-31 | $336.17 Million | $-200.55 Million | -0.597x | -115.40% |
| 2021-12-31 | $491.55 Million | $-136.14 Million | -0.277x | +91.93% |
| 2020-12-31 | $3.10 Million | $-10.63 Million | -3.431x | -704.88% |
| 2019-12-31 | $13.66 Million | $-5.83 Million | -0.426x | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more